RU2014140116A - Антитела против pdgf-c - Google Patents
Антитела против pdgf-c Download PDFInfo
- Publication number
- RU2014140116A RU2014140116A RU2014140116A RU2014140116A RU2014140116A RU 2014140116 A RU2014140116 A RU 2014140116A RU 2014140116 A RU2014140116 A RU 2014140116A RU 2014140116 A RU2014140116 A RU 2014140116A RU 2014140116 A RU2014140116 A RU 2014140116A
- Authority
- RU
- Russia
- Prior art keywords
- seq
- antibody
- amino acid
- cdr
- heavy chain
- Prior art date
Links
- 102100040681 Platelet-derived growth factor C Human genes 0.000 title claims abstract 8
- 108010017992 platelet-derived growth factor C Proteins 0.000 title claims abstract 8
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract 37
- 239000000427 antigen Substances 0.000 claims abstract 14
- 102000036639 antigens Human genes 0.000 claims abstract 14
- 108091007433 antigens Proteins 0.000 claims abstract 14
- 102000001393 Platelet-Derived Growth Factor alpha Receptor Human genes 0.000 claims abstract 4
- 108010068588 Platelet-Derived Growth Factor alpha Receptor Proteins 0.000 claims abstract 4
- 230000004913 activation Effects 0.000 claims abstract 2
- 230000001404 mediated effect Effects 0.000 claims abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract 2
- 239000003814 drug Substances 0.000 claims 21
- 239000012634 fragment Substances 0.000 claims 16
- 108020004707 nucleic acids Proteins 0.000 claims 10
- 150000007523 nucleic acids Chemical class 0.000 claims 10
- 102000039446 nucleic acids Human genes 0.000 claims 10
- 229940124597 therapeutic agent Drugs 0.000 claims 9
- 230000035772 mutation Effects 0.000 claims 8
- 230000001629 suppression Effects 0.000 claims 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 4
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 4
- 238000004519 manufacturing process Methods 0.000 claims 4
- 230000002265 prevention Effects 0.000 claims 4
- 102220470856 Interferon-induced helicase C domain-containing protein 1_S88A_mutation Human genes 0.000 claims 3
- 102220500287 Lysosomal alpha-glucosidase_D10G_mutation Human genes 0.000 claims 3
- 206010029113 Neovascularisation Diseases 0.000 claims 3
- 102220575917 Olfactory receptor 7D4_S84N_mutation Human genes 0.000 claims 3
- 102220593902 Serine/threonine-protein kinase PLK2_S14T_mutation Human genes 0.000 claims 3
- 239000002671 adjuvant Substances 0.000 claims 3
- 102220481134 cAMP-dependent protein kinase catalytic subunit beta_K13Q_mutation Human genes 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 210000004027 cell Anatomy 0.000 claims 3
- 238000002648 combination therapy Methods 0.000 claims 3
- 239000003085 diluting agent Substances 0.000 claims 3
- 238000002360 preparation method Methods 0.000 claims 3
- 102220067563 rs200327756 Human genes 0.000 claims 3
- 102200059932 rs28940878 Human genes 0.000 claims 3
- 102220011971 rs397515737 Human genes 0.000 claims 3
- 102200151426 rs5196 Human genes 0.000 claims 3
- 102200140931 rs794727301 Human genes 0.000 claims 3
- 102200076833 rs869312133 Human genes 0.000 claims 3
- 102220137027 rs886056062 Human genes 0.000 claims 3
- 102220514894 Heterogeneous nuclear ribonucleoprotein F_K87R_mutation Human genes 0.000 claims 2
- -1 carrier Substances 0.000 claims 2
- 238000003259 recombinant expression Methods 0.000 claims 2
- 102220219923 rs1060503389 Human genes 0.000 claims 2
- 102220198512 rs141447598 Human genes 0.000 claims 2
- 102200076656 rs34991226 Human genes 0.000 claims 2
- 238000003786 synthesis reaction Methods 0.000 claims 2
- 239000000969 carrier Substances 0.000 claims 1
- 238000010494 dissociation reaction Methods 0.000 claims 1
- 230000005593 dissociations Effects 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 210000004408 hybridoma Anatomy 0.000 claims 1
- 238000002955 isolation Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 102200010092 rs1060505039 Human genes 0.000 claims 1
- 102220085172 rs571537271 Human genes 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261637372P | 2012-04-24 | 2012-04-24 | |
| US61/637,372 | 2012-04-24 | ||
| EP12165314 | 2012-04-24 | ||
| EP12165314.1 | 2012-04-24 | ||
| US201261727231P | 2012-11-16 | 2012-11-16 | |
| US61/727,231 | 2012-11-16 | ||
| EP12192943.4 | 2012-11-16 | ||
| EP12192943 | 2012-11-16 | ||
| PCT/EP2013/058513 WO2013160359A1 (en) | 2012-04-24 | 2013-04-24 | Anti-pdgf-c antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2014140116A true RU2014140116A (ru) | 2016-06-10 |
Family
ID=49482233
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2014140116A RU2014140116A (ru) | 2012-04-24 | 2013-04-24 | Антитела против pdgf-c |
Country Status (13)
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104321343A (zh) | 2012-04-24 | 2015-01-28 | 斯鲁姆博詹尼克斯公司 | 抗pdgf-c抗体 |
| WO2017081171A1 (en) * | 2015-11-10 | 2017-05-18 | Paracrine Therapeutics Ab | Treatment of er-negative breast cancer with an pdgf-cc inhibitor and an anti estrogen |
| MA45493A (fr) * | 2016-06-27 | 2019-05-01 | Aicuris Anti Infective Cures Gmbh | Inhibiteurs d'entrée de hcmv. |
| US11352420B2 (en) | 2016-07-01 | 2022-06-07 | Paracrine Therapeutics Ab | Methods and compositions for PDGF-CC inhibition |
| KR101943083B1 (ko) | 2017-03-30 | 2019-01-29 | (주)케어젠 | 환경오염 물질에 대한 세포 보호 효과를 갖는 펩타이드 및 이의 용도 |
| KR101943081B1 (ko) | 2017-08-31 | 2019-01-29 | (주)케어젠 | 주름 개선 활성을 나타내는 펩타이드 및 이의 용도 |
| MX2020005809A (es) * | 2017-12-04 | 2020-08-20 | Salvat Lab Sa | Composicion topica oftalmica para tratar enfermedades del segmento posterior del ojo. |
| KR102726837B1 (ko) * | 2021-09-29 | 2024-11-07 | (주)케어젠 | 항노화 활성을 갖는 펩타이드 및 이의 용도 |
| WO2025038442A1 (en) * | 2023-08-11 | 2025-02-20 | Invetx, Inc. | Anti-il-5 antibodies and uses thereof |
| WO2025149667A1 (en) | 2024-01-12 | 2025-07-17 | Pheon Therapeutics Ltd | Antibody drug conjugates and uses thereof |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5468468A (en) * | 1989-02-09 | 1995-11-21 | The United States Of America, As Represented By The Secretary Of The Department Of Health & Human Services | Method for making a monoclonal antibody, monoclonal antibodies to α PD |
| WO1991019515A1 (en) | 1990-06-21 | 1991-12-26 | The Board Of Trustees Of The Leland Stanford Junior University | Oligomeric immunoglobulin constant domain mutant with enhanced complement-mediated cytolytic activity |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| DK0814159T3 (da) | 1990-08-29 | 2005-10-24 | Genpharm Int | Transgene, ikke-humane dyr, der er i stand til at danne heterologe antistoffer |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| CA2405246A1 (en) | 1990-12-03 | 1992-06-11 | Genentech, Inc. | Enrichment method for variant proteins with alterred binding properties |
| US5304118A (en) | 1992-12-16 | 1994-04-19 | Trese Michael T | Method for performing a vitrectomy on an eye |
| WO1999002567A2 (en) | 1997-07-08 | 1999-01-21 | Board Of Regents, The University Of Texas System | Compositions and methods for producing homoconjugates of antibodies which induce growth arrest or apoptosis of tumor cells |
| EP1064382B1 (en) | 1998-03-17 | 2008-08-20 | Genentech, Inc. | Polypeptides homologous to vegf and bmp1 |
| CN1330664A (zh) | 1998-09-30 | 2002-01-09 | 路德维格癌症研究所 | 血小板衍生生长因子c、其编码dna及其应用 |
| DK1137773T3 (da) * | 1998-12-07 | 2008-12-08 | Zymogenetics Inc | Væsktfaktorhomolog ZVEGF3 |
| US6432673B1 (en) * | 1998-12-07 | 2002-08-13 | Zymogenetics, Inc. | Growth factor homolog ZVEGF3 |
| WO2001028586A1 (en) | 1999-10-21 | 2001-04-26 | Zymogenetics, Inc. | Method of treating fibrosis |
| US7034200B2 (en) * | 2000-03-28 | 2006-04-25 | Ludwig Institute For Cancer Research | Non-human transgenic animals expressing platelet-derived growth factor C (PDGF-C) and uses thereof |
| MXPA02010011A (es) | 2000-04-11 | 2003-04-25 | Genentech Inc | Anticuerpos multivalentes y usos para los mismos. |
| GB0228409D0 (en) | 2002-12-06 | 2003-01-08 | Thromb X Nv | Pharmacological vitreolysis |
| US20050191304A1 (en) | 2003-07-25 | 2005-09-01 | Palmer Thomas E. | Method of treating hepatocellular carcinoma |
| WO2005087812A1 (en) | 2004-03-05 | 2005-09-22 | Ludwig Institute For Cancer Research | Multivalent antibody materials and methods for vegf/pdgf family of growth factors |
| WO2007124308A2 (en) | 2006-04-17 | 2007-11-01 | Ludwig Institute For Cancer Research | Methods and compositions for modulation of blood-neural barrier |
| CL2007002225A1 (es) * | 2006-08-03 | 2008-04-18 | Astrazeneca Ab | Agente de union especifico para un receptor del factor de crecimiento derivado de plaquetas (pdgfr-alfa); molecula de acido nucleico que lo codifica; vector y celula huesped que la comprenden; conjugado que comprende al agente; y uso del agente de un |
| WO2010033913A1 (en) | 2008-09-22 | 2010-03-25 | Icb International, Inc. | Antibodies, analogs and uses thereof |
| CN104321343A (zh) | 2012-04-24 | 2015-01-28 | 斯鲁姆博詹尼克斯公司 | 抗pdgf-c抗体 |
-
2013
- 2013-04-24 CN CN201380021028.7A patent/CN104321343A/zh active Pending
- 2013-04-24 WO PCT/EP2013/058513 patent/WO2013160359A1/en active Application Filing
- 2013-04-24 EP EP13722708.8A patent/EP2841454A1/en not_active Withdrawn
- 2013-04-24 MX MX2014012843A patent/MX2014012843A/es unknown
- 2013-04-24 US US14/404,052 patent/US9884910B2/en not_active Expired - Fee Related
- 2013-04-24 RU RU2014140116A patent/RU2014140116A/ru not_active Application Discontinuation
- 2013-04-24 AU AU2013254690A patent/AU2013254690B2/en not_active Expired - Fee Related
- 2013-04-24 KR KR1020147032459A patent/KR20150005631A/ko not_active Withdrawn
- 2013-04-24 BR BR112014025560A patent/BR112014025560A2/pt not_active IP Right Cessation
- 2013-04-24 JP JP2015507520A patent/JP2015515487A/ja active Pending
- 2013-04-24 NZ NZ724395A patent/NZ724395A/en unknown
- 2013-04-24 NZ NZ700274A patent/NZ700274A/en not_active IP Right Cessation
- 2013-04-24 CA CA2871528A patent/CA2871528A1/en not_active Abandoned
-
2014
- 2014-11-18 IN IN9717DEN2014 patent/IN2014DN09717A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2013160359A1 (en) | 2013-10-31 |
| CN104321343A (zh) | 2015-01-28 |
| MX2014012843A (es) | 2017-01-23 |
| JP2015515487A (ja) | 2015-05-28 |
| EP2841454A1 (en) | 2015-03-04 |
| NZ700274A (en) | 2016-10-28 |
| CA2871528A1 (en) | 2013-10-31 |
| US20150232546A1 (en) | 2015-08-20 |
| AU2013254690B2 (en) | 2017-12-07 |
| US9884910B2 (en) | 2018-02-06 |
| KR20150005631A (ko) | 2015-01-14 |
| BR112014025560A2 (pt) | 2017-07-04 |
| IN2014DN09717A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 2015-07-31 |
| AU2013254690A1 (en) | 2014-11-06 |
| NZ724395A (en) | 2018-03-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2014140116A (ru) | Антитела против pdgf-c | |
| JP7464764B2 (ja) | 抗ｒｏｒ１抗体とその作製及び使用方法 | |
| RU2014113304A (ru) | Анти-cd40-антитела, применение и методы | |
| CA3168654A1 (en) | Drug conjugate of eribulin derivative, preparation method therefor and application thereof in medicine | |
| RU2009136913A (ru) | Биспецифические связывающие агенты с межвидовой специфичностью | |
| RU2019134352A (ru) | Новые биспецифические антигенсвязывающие молекулы, обладающие способностью специфически связываться с cd40 и fap | |
| JP2018529667A (ja) | Ｔ細胞媒介免疫応答を調節するための組成物および方法 | |
| RU2014151788A (ru) | Молекула, специфически связывающаяся с rsv | |
| JP2018527919A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | ||
| RU2014109039A (ru) | Биспецифические антигенсвязывающие молекулы | |
| RU2013125459A (ru) | АНТИТЕЛА ПРОТИВ БЕЛКА РЕЦЕПТОРА c-Met | |
| JP2017534253A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | ||
| RU2013143358A (ru) | Анти-fgfr4 антитела и способы их применения | |
| JP2018500014A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | ||
| JP2020517248A (ja) | Ｌｒｉｇ‐１タンパク質に特異的な結合分子およびその用途 | |
| JP2016531915A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | ||
| JP2014527814A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | ||
| RU2015118180A (ru) | Антитела к бета-амилоиду | |
| RU2017114968A (ru) | Связывающие молекулы, а именно антитела, способные связываться с l1cam (cd171) | |
| RU2019134462A (ru) | Антитела, связывающиеся с steap-1 | |
| RU2014109093A (ru) | Антитела против нейрегулина и их применение | |
| JP2020533965A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | ||
| RU2015108797A (ru) | Антитела к jagged и способы их применения перекрестная ссылка на родственные заявки | |
| RU2016141285A (ru) | Биспецифические антигенсвязывающие полипептиды | |
| JP2020531003A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20180206 |